Based on the cost-benefit analysis performed by FDA, the rule will impose an unfunded mandate on the private sector of over $100 million annually and therefore the rule is subject to the requirements of the Act.
The rule imposing an unfunded mandate on the private sector is based on the FDA's cost-benefit analysis.